Implications of the Licensure of a Partially Efficacious Malaria Vaccine on Evaluating Second-generation Vaccines

Overview

Journal BMC Med

Publisher Biomed Central

Specialty General Medicine

Date 2013 Nov 16

PMID 24228861

Citations 8

Authors

Freya J I Fowkes

Julie A Simpson

James G Beeson

Affiliations

Soon will be listed here.

Abstract

Background: Malaria is a leading cause of morbidity and mortality, with approximately 225 million clinical episodes and >1.2 million deaths annually attributed to malaria. Development of a highly efficacious malaria vaccine will offer unparalleled possibilities for disease prevention and remains a key priority for long-term malaria control and elimination.

Discussion: The Malaria Vaccine Technology Roadmap's goal is to 'develop and license a first-generation malaria vaccine that has protective efficacy of more than 50%'. To date, malaria vaccine candidates have only been shown to be partially efficacious (approximately 30% to 60%). However, licensure of a partially effective vaccine will create a number of challenges for the development and progression of new, potentially more efficacious, malaria vaccines in the future. In this opinion piece we discuss the methodological, logistical and ethical issues that may impact on the feasibility and implementation of superiority, non-inferiority and equivalence trials to assess second generation malaria vaccines in the advent of the licensure of a partially efficacious malaria vaccine.

Conclusions: Selecting which new malaria vaccines go forward, and defining appropriate methodology for assessment in logistically challenging clinical trials, is crucial. It is imperative that the scientific community considers all the issues and starts planning how second-generation malaria vaccines will advance in the advent of licensure of a partially effective vaccine.

Citing Articles

Modelling population-level impact to inform target product profiles for childhood malaria vaccines.

Hogan A, Winskill P, Verity R, Griffin J, Ghani A BMC Med. 2018; 16(1):109.

PMID: 30001708 PMC: 6044028. DOI: 10.1186/s12916-018-1095-6.

Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.

Krishnarjuna B, Andrew D, MacRaild C, Morales R, Beeson J, Anders R Sci Rep. 2016; 6:20613.

PMID: 26865062 PMC: 4749986. DOI: 10.1038/srep20613.

Malaria eradication and elimination: views on how to translate a vision into reality.

Tanner M, Greenwood B, Whitty C, Ansah E, Price R, Dondorp A BMC Med. 2015; 13:167.

PMID: 26208740 PMC: 4514994. DOI: 10.1186/s12916-015-0384-6.

Malaria Vaccines: Progressing on a Bumpy Road.

Corradin G, Nebie I EBioMedicine. 2015; 1(1):6-7.

PMID: 26137504 PMC: 4457400. DOI: 10.1016/j.ebiom.2014.10.010.

Malaria Vaccines: Moving Forward After Encouraging First Steps.

Tran T, Portugal S, Draper S, Crompton P Curr Trop Med Rep. 2015; 2(1):1-3.

PMID: 25995985 PMC: 4435961. DOI: 10.1007/s40475-015-0041-3.

References

OMeara W, Mwangi T, Williams T, McKenzie F, Snow R, Marsh K . Relationship between exposure, clinical malaria, and age in an area of changing transmission intensity. Am J Trop Med Hyg. 2008; 79(2):185-91. PMC: 2547116. View

Duncan C, Hill A . What is the efficacy of the RTS,S malaria vaccine?. BMJ. 2011; 343:d7728. PMC: 3287289. DOI: 10.1136/bmj.d7728. View

Postema A, Myers M, Breiman R . Challenges in the development, licensure, and use of combination vaccines. Clin Infect Dis. 2001; 33 Suppl 4:S261-6. DOI: 10.1086/322560. View

Kester K, Cummings J, Ofori-Anyinam O, Ockenhouse C, Krzych U, Moris P . Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis. 2009; 200(3):337-46. DOI: 10.1086/600120. View

Agnandji S, Lell B, Soulanoudjingar S, Fernandes J, Abossolo B, Conzelmann C . First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. N Engl J Med. 2011; 365(20):1863-75. DOI: 10.1056/NEJMoa1102287. View

Briand V, Bottero J, Noel H, Masse V, Cordel H, Guerra J . Intermittent treatment for the prevention of malaria during pregnancy in Benin: a randomized, open-label equivalence trial comparing sulfadoxine-pyrimethamine with mefloquine. J Infect Dis. 2009; 200(6):991-1001. DOI: 10.1086/605474. View

Sagara I, Rulisa S, Mbacham W, Adam I, Sissoko K, Maiga H . Efficacy and safety of a fixed dose artesunate-sulphamethoxypyrazine-pyrimethamine compared to artemether-lumefantrine for the treatment of uncomplicated falciparum malaria across Africa: a randomized multi-centre trial. Malar J. 2009; 8:63. PMC: 2678145. DOI: 10.1186/1475-2875-8-63. View

Olotu A, Fegan G, Wambua J, Nyangweso G, Awuondo K, Leach A . Four-year efficacy of RTS,S/AS01E and its interaction with malaria exposure. N Engl J Med. 2013; 368(12):1111-20. PMC: 5156295. DOI: 10.1056/NEJMoa1207564. View

Piaggio G, Elbourne D, Altman D, Pocock S, Evans S . Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006; 295(10):1152-60. DOI: 10.1001/jama.295.10.1152. View

10.

Premji Z, Umeh R, Owusu-Agyei S, Esamai F, Ezedinachi E, Oguche S . Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One. 2009; 4(8):e6682. PMC: 2724683. DOI: 10.1371/journal.pone.0006682. View

11.

Scott I . Non-inferiority trials: determining whether alternative treatments are good enough. Med J Aust. 2009; 190(6):326-30. DOI: 10.5694/j.1326-5377.2009.tb02425.x. View

12.

Agnandji S, Lell B, Fernandes J, Abossolo B, Methogo B, Lumeka Kabwende A . A phase 3 trial of RTS,S/AS01 malaria vaccine in African infants. N Engl J Med. 2012; 367(24):2284-95. PMC: 10915853. DOI: 10.1056/NEJMoa1208394. View

13.

Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menendez C . Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One. 2009; 4(11):e7871. PMC: 2776302. DOI: 10.1371/journal.pone.0007871. View

14.

Schwartz L, Brown G, Genton B, Moorthy V . A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J. 2012; 11:11. PMC: 3286401. DOI: 10.1186/1475-2875-11-11. View

15.

McCarthy J, Marjason J, Elliott S, Fahey P, Bang G, Malkin E . A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720. PLoS One. 2011; 6(9):e24413. PMC: 3176224. DOI: 10.1371/journal.pone.0024413. View

16.

Clemens J, Brenner R, Rao M, Tafari N, Lowe C . Evaluating new vaccines for developing countries. Efficacy or effectiveness?. JAMA. 1996; 275(5):390-7. View

17.

Moorthy V, Reed Z, Smith P . Measurement of malaria vaccine efficacy in phase III trials: report of a WHO consultation. Vaccine. 2007; 25(28):5115-23. DOI: 10.1016/j.vaccine.2007.01.085. View

18.

Thera M, Doumbo O, Coulibaly D, Laurens M, Ouattara A, Kone A . A field trial to assess a blood-stage malaria vaccine. N Engl J Med. 2011; 365(11):1004-13. PMC: 3242358. DOI: 10.1056/NEJMoa1008115. View

19.

Sirima S, Tiono A, Gansane A, Diarra A, Ouedraogo A, Konate A . The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. Malar J. 2009; 8:48. PMC: 2662869. DOI: 10.1186/1475-2875-8-48. View

20.

Lievens M, Aponte J, Williamson J, Mmbando B, Mohamed A, Bejon P . Statistical methodology for the evaluation of vaccine efficacy in a phase III multi-centre trial of the RTS, S/AS01 malaria vaccine in African children. Malar J. 2011; 10:222. PMC: 3167766. DOI: 10.1186/1475-2875-10-222. View